These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37436339)

  • 1. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan.
    Gomes KLG; da Silva RE; da Silva JB; Bosio CGP; Novaes MRCG
    Cytotherapy; 2023 Oct; 25(10):1113-1123. PubMed ID: 37436339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan.
    Gomes KLG; da Silva RE; da Silva Junior JB; Novaes MRCG
    Cytotherapy; 2022 May; 24(5):557-566. PubMed ID: 35227603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study.
    Cai Y; Sui L; Wang J; Qian W; Peng Y; Gong L; Wu W; Gao Y
    BMC Med; 2024 Sep; 22(1):421. PubMed ID: 39334246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of GMP for marketing authorization of ATMPs: comparison in the US, the EU, Japan and South Korea.
    Shin H; Kim E
    Regen Med; 2022 May; 17(5):283-297. PubMed ID: 35232285
    [No Abstract]   [Full Text] [Related]  

  • 6. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
    Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand.
    Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P
    Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
    Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
    Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
    Kim J; Park J; Song SY; Kim E
    Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial resistance and the guidelines of the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH).
    Marion H
    Rev Sci Tech; 2012 Apr; 31(1):299-306. PubMed ID: 22849284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
    Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Harmonisation of the Marketing Authorisation Application dossier: perspectives due to harmonised requirements. Assessing Rules and the Common Technical Document].
    Menges K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):748-56. PubMed ID: 18584104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation.
    Detela G; Lodge A
    Mol Ther Methods Clin Dev; 2019 Jun; 13():205-232. PubMed ID: 30815512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
    de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
    Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.